PNC Financial Services Group Inc. Has $1.65 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Key Points

• PNC Financial Services Group Inc. reduced its stake in Hologic, Inc. by 31.6%, selling 12,315 shares and leaving them with a total of 26,699 shares valued at approximately $1.649 million.
• Hologic reported a quarterly earnings per share (EPS) of $1.08, exceeding analysts' expectations by $0.03, with revenues totaling $1.02 billion, marking a 1.2% increase from the previous year.
• Analysts have a consensus rating of "Moderate Buy" for Hologic, with a consensus target price of $77.83, as various institutions have recently adjusted their ratings and price targets for the company's stock.

PNC Financial Services Group Inc. lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 31.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,699 shares of the medical equipment provider's stock after selling 12,315 shares during the quarter. PNC Financial Services Group Inc.'s holdings in Hologic were worth $1,649,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of HOLX. Beverly Hills Private Wealth LLC raised its stake in Hologic by 3.6% during the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock valued at $320,000 after acquiring an additional 180 shares in the last quarter. Allworth Financial LP raised its stake in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after acquiring an additional 216 shares in the last quarter. Dark Forest Capital Management LP raised its stake in Hologic by 7.9% during the 4th quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock valued at $220,000 after acquiring an additional 223 shares in the last quarter. Baker Avenue Asset Management LP raised its stake in shares of Hologic by 0.5% in the 4th quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock worth $3,031,000 after buying an additional 225 shares in the last quarter. Finally, Integrated Advisors Network LLC raised its stake in shares of Hologic by 5.4% in the 1st quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock worth $346,000 after buying an additional 289 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. UBS Group boosted their price objective on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research note on Thursday, July 31st. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and boosted their price objective for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. Evercore ISI boosted their price objective on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Finally, Morgan Stanley boosted their price objective on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Ten research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $77.83.

Hologic Stock Down 0.1%

Shares of HOLX stock traded down $0.07 on Monday, reaching $67.99. 1,173,272 shares of the company's stock traded hands, compared to its average volume of 1,762,824. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.39. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The company has a market capitalization of $15.12 billion, a P/E ratio of 28.21, a price-to-earnings-growth ratio of 2.47 and a beta of 0.49. The business's 50 day moving average price is $65.21 and its two-hundred day moving average price is $62.61.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%. The business's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.06 earnings per share. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.